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Abstract: Interleukin-2 (IL-2) is a cytokine centrally involved in the regulation of immune tolerance and
activation by its effects on CD4+ T regulatory (Treg) cells and cytotoxic effector lymphocytes, respec-
tively. Due to these properties IL-2 immunotherapy has been used, as low-dose IL-2, in the treatment
of autoimmune and chronic-inflammatory disorders; conversely, at high doses, IL-2 has shown efficacy
in a subset of patients with metastatic cancer. Recent advances have highlighted the possibility of using
improved IL-2-based therapies, such IL-2-antibody complexes (IL-2 complexes), able to selectively and
potently stimulate either Treg cells or cytotoxic effector cells. This article discusses the properties and
clinical implications of IL-2 and IL-2 complexes.
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ABSTRACT
Interleukin-2 (IL-2) is a cytokine cen-
trally involved in the regulation of im-
mune tolerance and activation by its ef-
fects on CD4+ T regulatory (Treg) cells 
and cytotoxic effector lymphocytes, 
respectively. Due to these properties 
IL-2 immunotherapy has been used, as 
low-dose IL-2, in the treatment of au-
toimmune and chronic-inflammatory 
disorders; conversely, at high doses, 
IL-2 has shown efficacy in a subset of 
patients with metastatic cancer. Recent 
advances have highlighted the possibil-
ity of using improved IL-2-based thera-
pies, such IL-2-antibody complexes (IL-
2 complexes), able to selectively and 
potently stimulate either Treg cells or 
cytotoxic effector cells. This article dis-
cusses the properties and clinical impli-
cations of IL-2 and IL-2 complexes.
Background
Lymphocyte homeostasis and function 
crucially depends on cytokine signals, 
most notably common γ chain (γc) cy-
tokines, which include interleukin-2 
(IL-2), IL-4, IL-7, IL-9, IL-15, and 
IL-21 (1). Of these cytokines, IL-2 is 
special in being implicated in immune 
tolerance and immune activation (2-4). 
Many immune cells have been reported 
to produce IL-2, including CD4+ help-
er T cells, CD8+ T cells, natural killer 
(NK) cells, NKT cells, activated den-
dritic cells and mast cells (3). During 
steady-state conditions, the main source 
of the low background levels of IL-2 
are CD4+ helper T cells, while follow-
ing immune activation large amounts 
of IL-2 are synthesised by both CD4+ 
helper and CD8+ T cells, with some 
contribution also from the aforemen-
tioned other immune cells (3).
IL-2 acts on cells expressing either di-
meric IL-2 receptors (IL-2R) consisting 
of IL-2Rβ (CD122) and the γc (CD132) 
or trimeric IL-2Rs made of CD122 and 
γc plus the IL-2Rα subunit (also called 
CD25), with trimeric IL-2Rs display-
ing a 10–100-fold higher affinity for 
IL-2 compared to dimeric IL-2Rs (5, 6). 
Dimeric IL-2Rs are most prominent on 
antigen-experienced (memory) CD8+ T 
cells and NK cells, while trimeric IL-
2Rs are typically expressed at high lev-
els by thymus-derived (‘natural’) CD4+ 
T regulatory (Treg) cells and recently-
activated effector T cells and, at low 
to very low levels, on other immune 
(including group 2 innate lymphoid 
cells) and non-immune cells (such as 
endothelial cells, see next chapters) (3, 
7, 8). Thus, low doses of IL-2, such as 
steady-state homeostatic levels, neces-
sitate the expression of high trimeric 
IL-2R expression levels and appear to 
mainly support the maintenance of Treg 
cells (9, 10), which play a key role in 
peripheral immune tolerance by restrict-
ing responses of (autoreactive) effector 
CD4+ and CD8+ T cells. Conversely, 
high doses of IL-2 are able to also ac-
tivate dimeric IL-2Rs and by that virtue 
strongly stimulate cytotoxic lympho-
cytes, including CD8+ T and NK cells, 
in addition to activating Treg cells (11).
These observations highlight the some-
what opposed roles of IL-2 in activat-
ing and containing immune responses, 
thereby regulating the ratio of effector 
T cells to Treg cells (Teff:Treg ratio). 
In immune pathologies, the lack of 
therapeutics able to selectively boost 
Treg cells has – at least until recently 
– focused clinical management of pa-
tients with inflammatory and autoim-
mune diseases on the use of immuno-
suppressive agents targeting effector 
T cells, thus somewhat correcting the 
Teff:Treg ratio. However, this approach 
comes with the disadvantage of sup-
pressing both harmful and protective 
immune responses. Likewise, the use 
of high-dose IL-2 to stimulate effector 
T cells against metastatic cancer has 
shown some success but has also suf-
fered from shortcomings, including the 
concomitant stimulation of Treg cells 
able to dampen anti-tumour immune 
responses as well as the appearance of 
IL-2-induced toxic adverse events.
Modulation of T cell responses by IL-2 and IL-2 complexes
O. Boyman, A.G.A. Kolios, M.E. Raeber
S-55
Modulation of T cell responses by IL-2 and IL-2 complexes / O. Boyman et al.
For several years, we have been study-
ing modified IL-2 formulations for se-
lective stimulation of either Treg cells 
for the treatment of autoimmune disor-
ders and graft-related immunopathol-
ogy or preferential activation of cyto-
toxic lymphocytes for cancer immuno-
therapy. We have shown that so-called 
IL-2-antibody complexes (briefly, IL-2 
complexes), consisting of IL-2 conju-
gated to a particular anti-IL-2 monoclo-
nal antibody (mAb), are able to selec-
tively stimulate either CD4+ Treg cells 
or CD8+ T and NK cells, depending on 
the anti-IL-2 mAb used (3, 12-16), thus 
leading to specific immune modulation 
without immunosuppression.
CD4+ Treg cell-stimulating 
IL-2 complexes
As mentioned before, CD4+ Treg cells 
constitutively express high levels of 
CD25 (7), which explains the high 
sensitivity of Treg cells to IL-2 in vitro 
and in vivo (9, 17-22). Thus, Treg cell 
homeostasis depends on IL-2 signals 
in vivo and animals and humans defi-
cient in IL-2, CD25 or CD122 develop 
systemic autoimmune disease owing to 
a reduction in Treg cell numbers (2-4, 
10, 22), highlighting the central role of 
IL-2 in Treg cell development, survival 
and function. IL-2 is also important in 
Treg cells for the upregulation of CD25 
and the maintenance of the signature 
transcription factor forkhead box P3 
(FoxP3), both for thymus-derived 
(‘natural’) and peripherally-derived 
(‘induced’) Treg cells (2, 3, 23-26).
As for humans, low-dose IL-2 immuno-
therapy was recently tested in patients 
with chronic graft-versus-host disease 
(GvHD) as well as in patients with 
hepatitis C virus-induced cryoglobuli-
naemic vasculitis. These disorders are 
associated with low Treg cell numbers 
as assessed by circulating Treg cell 
counts, thus resulting in an imbalance 
of the Teff:Treg ratio, which has been 
proposed to underly the immunopa-
thology observed with these disorders 
that are usually treated using immu-
nosuppressive agents. The new studies 
showed that low-dose IL-2 resulted in 
an increase in peripheral blood Treg cell 
counts, which in chronic GvHD was as-
sociated with disease improvement in 
12 out of 23 and disease stabilisation 
in the remainder of the treated patients 
(27, 28), and in cryoglobulinaemic vas-
culitis resulted in improvement in 8 out 
of 10 treated patients (29), whereas no 
apparent stimulation of effector T cells 
or severe side effects occurred (10).
With the use of Treg cell-selective IL-2 
complexes, such as IL-2/JES6-1 com-
plexes (12) or IL-2/5344 complexes 
(14), IL-2 can be targeted in a very di-
rected manner to CD25+ FoxP3+ Treg 
cells. This selectivity stems from the 
covering of the CD122/γc-binding site 
of IL-2 by the anti-IL-2 mAb, thus al-
lowing only cells expressing very high 
levels of CD25, i.e. Treg cells under 
steady-state conditions, to recognise 
and compete for these IL-2 complexes, 
as cells expressing only dimeric IL-2Rs 
cannot utilise their CD122 anymore to 
bind IL-2 in this form (3). Use of Treg 
cell-expanding IL-2 complexes proved 
to be beneficial for the treatment of 
several mouse models of pathologic in-
flammation or autoimmunity, including 
a T cell-mediated form of asthma (30), 
autoimmune diabetes in non-obese dia-
betic mice (31), experimental autoim-
mune encephalomyelitis (13), experi-
mental myasthenia (32), and collagen-
induced arthritis (33). Moreover, use 
of a short course of Treg cell-specific 
IL-2 complexes prior to transplanta-
tion induced long-term acceptance of 
fully major histocompatibility complex 
(MHC)-mismatched pancreatic islet 
grafts in over 80% of recipient mice 
(13). Based on these data, generation 
and development of appropriate JES6-
1-type anti-human IL-2 mAbs and IL-2 
complexes could prove valuable for the 
treatment of chronic inflammatory and 
autoimmune disorders (3, 10, 34).
CD8+ and NK cell-stimulating 
IL-2/mAb complexes
In contrast to low-dose IL-2, high-dose 
IL-2 immunotherapy has been used 
already since the early 1980s in the 
treatment of cancer, leading to clinical 
responses in 13–16% of patients with 
metastatic melanoma and metastatic 
renal cell carcinoma (35, 36), with as 
much as 5–10% of these patients sur-
viving for 20 years and more. Based 
on these data, high-dose IL-2 treatment 
was recommended as a first-line ther-
apy in certain stage IV melanoma pa-
tients (37). The rate of overall survival 
could be improved by using combined 
vaccination strategies or higher doses 
of IL-2, the latter of which is hampered 
by the development of dose-dependent 
IL-2-induced side effects, termed vas-
cular leak syndrome (VLS), which 
resembles the clinical manifestations 
of septic shock (34, 38, 39). Another 
potential disadvantage of IL-2-based 
cancer immunotherapy relates to the 
property of IL-2 in promoting homeo-
stasis and survival of Treg cells, which 
are able to inhibit or dampen T cell re-
sponses to self-antigens, including tu-
mour antigens (20, 40).
To counter these disadvantages, modi-
fied IL-2 formulations have been gen-
erated, including mutated IL-2 variants, 
IL-2 fusion proteins and CD8+ T and 
NK cell-directed IL-2 complexes (41). 
We favour IL-2 complexes, as the bind-
ing of the mAb protects IL-2 from scav-
enger molecules and from interacting 
with and damaging endothelial cells (3, 
15); once IL-2 complexes have reached 
their target cells (i.e. cytotoxic CD8+ T 
cells and NK cells), unmodified IL-2 
can interact with and fully stimulate the 
IL-2R and thus the effector cells (3, 15).
In our original work, we demonstrated 
that the combination of recombinant 
mouse IL-2 with a particular anti-mouse 
IL-2 mAb (clones S4B6 or JES6-5H4) 
led to the formation of IL-2 complexes, 
which markedly enhanced the in vivo 
activity of IL-2, thus leading to vigor-
ous expansion of CD8+ T cells and NK 
cells, while CD4+ CD25+ FoxP3+ Treg 
cells were barely stimulated by this form 
of IL-2 (12). This principle also applied 
to other cytokines, including IL-4, IL-6, 
IL-7 and IL-15 (42-46). Subsequently, 
cytokine complexes using IL-2, IL-4, 
IL-7 and IL-15 were assessed in differ-
ent murine tumour models where IL-2 
complexes appeared to show the most 
favourable anti-tumour properties (15, 
16, 41, 47). Most notably, IL-2 in the 
form of IL-2 complexes was not only 
more potent in stimulating CD8+ T cells 
and NK cells but also caused signifi-
cantly less adverse effects compared to 
standard high-dose IL-2 (15). Accord-
ingly, administration of IL-2 complexes 
S-56
Modulation of T cell responses by IL-2 and IL-2 complexes / O. Boyman et al.
to normal mice led to marked expansion 
of endogenous CD8+ T and NK cells, 
which exhibited potent anti-tumour re-
sponses against syngeneic B16F10 mel-
anomas, growing either intradermally 
or as pulmonary nodules following in-
travenous injection, as well as intrader-
mal nodules of MC38 colon carcinoma 
or LLC Lewis lung carcinoma (15, 16). 
Use of IL-2 complexes at a low concen-
tration of IL-2, i.e. 5,000 international 
units (IU) per injection, generated an 
anti-B16F10 response that was compa-
rable to the therapeutic effect achieved 
by using the highest tolerated dose of 
conventional IL-2 immunotherapy, i.e. 
200’000 IU per injection. However, 
in contrast to 200,000 IU IL-2, which 
caused significant toxicity (i.e. VLS), 
such as prominent pulmonary oedema 
and significant liver cell damage, IL-2 
complexes at 5,000 IU caused only neg-
ligible side effects.
These improved therapeutic features of 
IL-2 complexes stimulating CD8+ T and 
NK cells are due to reversible modifica-
tions of IL-2 following anti-IL-2 mAb 
binding, thus leading to the selective di-
rection of IL-2 towards cells expressing 
high levels of the intermediate-affinity 
IL-2R consisting of CD122 and γc, but 
do not depend on CD25 expression (3, 
12, 14, 15, 34). The underlying mecha-
nism appears to rely on the covering of 
the CD25-binding epitope of IL-2 by 
this type of anti-IL-2 mAb (3, 12, 14, 15, 
34). Therefore, cells expressing high lev-
els of CD25 and depending on CD25 for 
their IL-2 binding, such as CD4+ CD25+ 
Treg cells and endothelial cells, do not 
become efficiently stimulated by such 
IL-2 complexes, thereby disfavouring 
the establishment of an immunosuppres-
sive environment and circumventing the 
generation of endothelial cell damage 
leading to VLS (3, 15, 22). Additionally, 
IL-2 complexes show a roughly 20-40 
times increased in vivo half-life com-
pared to IL-2 (3, 14, 41), thereby provid-
ing a more even and sustained stimula-
tion of IL-2R+ immune cells.
Collectively, based on preclinical data 
IL-2 complexes show promising ef-
fects in several models of immunopa-
thology and cancer, thus warranting 
development of appropriate clinical-
grade IL-2 complexes.
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